Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805008 | 1.00 | ADRB3 (0.56) | ADRB3ADRB1 | |
| SCHEMBL6680458 | 0.92 | ADRB3 (0.54) | ADRB3ADRB1 | |
| SCHEMBL6806634 | 0.91 | ADRB3 (0.59) | ADRB3ADRB1 | |
| SCHEMBL6798555 | 0.88 | ADRB3 (0.51) | ADRB3ADRB1 | |
| SCHEMBL6682351 | 0.88 | ADRB3 (0.51) | ADRB3ADRB1 | |
| SCHEMBL6552720 | 0.86 | ADRB3 (0.61) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6539203 | 0.85 | ADRB3 (0.60) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6539196 | 0.85 | ADRB3 (0.60) | ADRB3ADRB1 | |
| SCHEMBL6539611 | 0.85 | ADRB3 (0.58) | ADRB3ADRB1 | |
| SCHEMBL6539613 | 0.85 | ADRB3 (0.58) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ADRB3 150/4885ADRB1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.